Drug Type ASO |
Synonyms QR 313, QRX-313 |
Target |
Action modulators |
Mechanism COL7A1 gene modulators |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epidermolysis Bullosa Dystrophica, Pasini Type | Phase 2 | United States | 02 Jul 2018 | |
Epidermolysis Bullosa Dystrophica, Pasini Type | Phase 2 | France | 02 Jul 2018 | |
Epidermolysis Bullosa Dystrophica, Pasini Type | Phase 2 | Spain | 02 Jul 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | United States | 21 Mar 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | Czechia | 21 Mar 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | France | 21 Mar 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | Germany | 21 Mar 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | Spain | 21 Mar 2018 | |
Epidermolysis Bullosa Dystrophica | Phase 2 | United Kingdom | 21 Mar 2018 |